Please login to the form below

Not currently logged in
Email:
Password:

skin cancer

This page shows the latest skin cancer news and features for those working in and with pharma, biotech and healthcare.

Vyriad inks immunotherapy alliance with Merck/Pfizer

Vyriad inks immunotherapy alliance with Merck/Pfizer

The drug – sold as Bavencio – has been approved for skin cancer Merkel cell carcinoma and bladder cancer, but in February failed a trial as a second-line therapy for non-small ... cell lung cancer and also had a knockback in third-line stomach cancer

Latest news

  • J&J pays $140m upfront for cancer-busting virus firm BeneVir J&J pays $140m upfront for cancer-busting virus firm BeneVir

    cancer, but also because it has to be injected directly into tumours rather than systemically, increasing the complexity of treatment. ... that the promise of oncolytic viruses will come to fruition when they are used in combination with other cancer

  • Regeneron’s Dupixent and Praluent fall short Regeneron’s Dupixent and Praluent fall short

    an FDA verdict in skin cancer in October but will be sixth in the class to market. ... The drug is backed up by a series of bispecific antibodies for cancer indications.

  • Sanofi’s latecomer PD-1 gets date for FDA verdict Sanofi’s latecomer PD-1 gets date for FDA verdict

    The FDA has set a deadline of 28 October for its review of Sanofi’s cemiplimab for a form of skin cancer, as the company tries to join the fast-growing ... The US regulator has given a priority review for PD-1-targeting cemiplimab because its first

  • BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

    drug. Opdivo and Yervoy have already shown their worth in melanoma, with BMS claiming approval for the combination in that form of skin cancer in 2015, and is also being tested ... Roche has also reported Sutent-topping results with it’s combination of

  • Incyte/Merck trial failure bodes ill for IDO class Incyte/Merck trial failure bodes ill for IDO class

    Incyte/Merck trial failure bodes ill for IDO class. The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone. ... a form of skin cancer, but was unable to show any improvement over Keytruda alone on progression-free

More from news
Approximately 18 fully matching, plus 133 partially matching documents found.

Latest Intelligence

  • Digital health Digital health

    What digital health has delivered to date is amazing. The examples are legion: an application which can differentially diagnose lesions on skin with 20-30 times more accuracy than a doctor ... when it comes to skin cancer, or HealthTap’s Dr AI which

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • CytomX appoints Rachel Humphrey chief medical officer CytomX appoints Rachel Humphrey chief medical officer

    Before her time at AZ and Eli Lilly, Humphrey was also VP of product development at Bristol-Myers Squibb where she led all aspects of clinical development of the skin-cancer

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Kite Pharma appoints Zelboraf scientist as CMO. Keith Nolop joins US cancer biotech from Plexxikon. ... Dr Keith Nolop, one of the chief scientists behind the development of Roche's personalised skin cancer drug Zelboraf, has been appointed chief medical

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Is fear an effective driver of behaviour change?

    Liz, who knows she has a high risk for skin cancer due to family history and skin type, will be more likely to apply sun cream (provided it is easy for ... Leo, who knows he has a lower risk of skin cancer, or for whom the cost or convenience of applying

  • When is sun safety doing more harm than good?

    New figures from  Cancer Research UK warn that people over 65 are around seven times more likely to develop malignant melanoma - a type of skin cancer - compared to 40 years ago. ... Thankfully campaigns from charities such as Cancer Research UK that

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics